Atlas Trials

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older

Clinical trial NCT05553301 · COMPLETED

Trial details

NCT number
NCT05553301
Sponsor
Sanofi Pasteur, a Sanofi Company
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Influenza Immunization
Start date
2022-10-03
Primary completion
2024-01-19
Enrollment
560

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.